Mainz advanced adenoma biomarkers feasibility study results

Create PDF

ColoAlert, the company’s flagship product, is an at-home, early-detection diagnostic test for colorectal cancer based on real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples. The test is CE marked; Mainz is running a pivotal FDA clinical study for U.S. regulatory approval.